recofonlimab

Recofonlimab (JS003) is a recombinant humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), developed by Junshi Biosciences (Shanghai JunTop Biosciences). It works by binding to PD-L1 on the surface of tumor cells and antigen-presenting cells, blocking its interaction with the PD-1 receptor on T cells. This blockade relieves the inhibitory effect on T-cell activation and restores the anti-tumor immune response. Recofonlimab is currently being evaluated in Phase 3 clinical trials, particularly for the treatment of small cell lung cancer (SCLC) and other solid tumors, often in combination with other therapies like toripalimab or chemotherapy.

Other names

偌考奇拜单抗Ruokaoqibai monoclonal antibody